Genefrontier Corporation
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2031
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 15, 2027The maintenance fee for High-Speed Maturation Method for an Oligonucleotide Library for the Purpose of Preparing a Protein Library (US 9,133,452) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due May 3, 2027The maintenance fee for Composition for Synthesizing Protein with Reduced Lipopolysaccharide Contamination, Method for Producing Protein Using Said Composition (US 9,175,327) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Sep 22, 2027The maintenance fee for Efficient method for displaying protein multimer (US 9,289,742) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Nov 5, 2027The maintenance fee for Human Antibody Against Aggrecanase-Type Adamts Species for Therapeutics of Aggrecanase-Related Diseases (US 10,640,573) comes due Nov 5, 2027. Unpaid by May 5, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,617,533 | Composition for Synthesizing Protein with Reduced Lipopolysaccharide Contamination, Method for Producing Protein Using Said Composition In force · High confidence | In force | High confidence | |
| US 9,133,452 | High-Speed Maturation Method for an Oligonucleotide Library for the Purpose of Preparing a Protein Library In force · High confidence | In force | High confidence | |
| US 9,175,327 | Composition for Synthesizing Protein with Reduced Lipopolysaccharide Contamination, Method for Producing Protein Using Said Composition In force · High confidence | In force | High confidence | |
| US 10,865,247 | Anti-Human CD69 Antibody, and Use Thereof for Medical Purposes In force · High confidence | In force | High confidence | |
| US 10,301,618 | Efficient Method for Displaying Protein Multimer In force · Medium confidence | In force | Medium confidence | |
| US 9,289,742 | Efficient method for displaying protein multimer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,640,573 | Human Antibody Against Aggrecanase-Type Adamts Species for Therapeutics of Aggrecanase-Related Diseases In force · Medium confidence | In force | Medium confidence | |
| US 12,565,517 | Cyclic Peptide Having CTLA-4 Inhibitory Activity and Use Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 1 patent in force now held by others · 3 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 abandoned